Skip to main content
. Author manuscript; available in PMC: 2015 Sep 1.
Published in final edited form as: Clin Cancer Res. 2014 Sep 1;20(17):4499–4510. doi: 10.1158/1078-0432.CCR-14-0348

Figure 4. LCS6-variant patients do not have improved OS with the addition of chemotherapy for double wt patients.

Figure 4

(A) Median OS according to the KRAS 3′-UTR LCS6 SNP genotype status in the double (KRAS and BRAF) wt patients’ population treated with anti-EGFR moAbs monotherapy as salvage treatment. (B) Median OS according to the KRAS 3′-UTR LCS6 SNP genotype status in the double (KRAS and BRAF) wt patients’ population treated with anti-EGFR moAbs based combination chemotherapy as salvage treatment. (C) Median OS according to type of therapy in the double (KRAS and BRAF) wt KRAS 3′-UTR LCS6 SNP carriers. (D) Median OS according to type of therapy in the double (KRAS and BRAF) wt non-KRAS 3′-UTR LCS6 SNP carriers.